Danijela Marojević Glibo and Sandra Marinović Kulišić*

Department of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Croatia

*Corresponding Author: Sandra Marinović Kulišić, Department of Dermatology and Venereology, University Hospital Centre Zagreb, School of Medicine University of Zagreb, Croatia.

Received: June 10, 2024; Published: July 08, 2024

Abstract

Necrobiosis lipoidica is a rare and idiopathic disorder of collagen degeneration presenting with granulomatous response [1]. The main complication is ulceration that usually occurs after trauma, mostly in patients with diabetes mellitus [2]. The disease has variable progression and scarring but is typically chronic with small risk of SCC developing in longstanding lesions [3]. The disease course appears more severe in men as they have a higher risk of ulceration in the lesions, reported in 58% of males. On the other hand only 15% of females are hit with this scenario. Histopathologically, thickening of blood vessel walls and fat deposition are seen [2]. Direct immunofluorescence microscopy shows IgM, IgA, fibrinogen, and C3 in the blood vessels causing vascular thickening [4]. Most treatments are not very satisfactory [5]. One of the few methods than have been successful are injections of steroid into the active inflamed borders or local potent steroid [6]. To certain individuals PUVA treatment can be beneficial.Calcineurin inhibitors have anti-inflammatory and immunomodulatory effects which can help in treatment of necrobiosis lipoidica [7]. Topical tacrolimus has been shown to be effective in resolving ulceration associated with necrobiosis lipoidica [8]. The monoclonal antibodie infliximab and etanercept- fusion protein made up of the Fc portion of human IgG, have been found to be effective as monotherapy for ulcerating necrobiosis lipoidica [9].

Keywords: Necrobiosis Lipoidica; Diagnosis; PUVA Therapy

References

1. Franklin C., et al. “Ulcerated necrobiosis lipoidica as a rare cause for chronic leg ulcers: case report series of ten patients”. International Wound Journal5 (2015): 548-554.
2. Lepe K., et al. “Necrobiosis Lipoidica”. StatPearls Publishing (2023).
3. Lim C., et al. “Squamous cell carcinoma arising in an area of long-standing necrobiosis lipoidica”. Journal of Cutaneous Pathology 8 (2006): 581-583.
4. Ullman S and Dahl M V. “Necrobiosis lipoidica. An immunofluorescence study”. Archives of Dermatology12 (1977): 1671-1673.
5. Reid S D., et al. “Update on necrobiosis lipoidica: A review of etiology, diagnosis, and treatment options”. Journal of the American Academy of Dermatology5 (2013): 783-791.
6. Erfurt-Berge C., et al. “Comorbidity and therapeutic approaches in patients with necrobiosis lipoidica”. Dermatology (Basel, Switzerland)1 (2022): 148-155.
7. Imadojemu S and Rosenbach M. “Advances in inflammatory granulomatous skin diseases”. Dermatologic Clinics 1 (2019): 49-64.
8. Clayton T H and Harrison P V. “Successful treatment of chronic ulcerated necrobiosis lipoidica with 0.1% topical tacrolimus ointment”. The British Journal of Dermatology3 (2005): 581-582.
9. Dissemond J., et al. “Systemic therapies for leg ulcers”. Journal Der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology],7 (2018): 873-890.
10. Sibbald C., et al. “Necrobiosis Lipoidica”. Dermatology Clinics3 (2015): 343-360.
11. Piacquadio D and Nelson D B. “Alginates: A “new” dressing alternative: A “new” dressing alternative”. The Journal of Dermatologic Surgery and Oncology11 (1992): 992-995.

Citation

Citation: Danijela Marojević Glibo and Sandra Marinović Kulišić. “Supportive Bio-Occlusive Alginate Dressing with Medical Chestnut Honey in Necrobiosis Lipoidice Treatment". Acta Scientific Clinical Case Reports 5.8 (2024): 24-25.

Copyright

Copyright: © 2024 Danijela Marojević Glibo and Sandra Marinović Kulišić. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.